October 22, 2025
Rare earths are becoming a valuation issue, not just a geopolitics headline
If you’re prepping for investment banking interviews, the cleanest market story here is the renewed U.S.-China fight over rare earths. It’s not just a tariff story. It’s a supply-chain control story, and that’s much more useful in an interview because it connects directly to margins, working capital, capex, valuation multiples, and deal strategy.
China announced strict new restrictions on rare earth exports. Foreign firms will need government approval before exporting products from China that contain even trace amounts of certain rare earths. That matters because rare earths are used across semiconductors, electric vehicles, defense systems, motors, drones, and other advanced technologies.
The core issue is concentration. China accounts for close to 70% of global rare earth output, producing roughly 270,000 tons annually versus about 45,000 tons in the United States. The U.S. also has zero refined production of several highlighted rare earth elements, which makes the refining bottleneck just as important as mining supply.
President Trump responded by threatening a 100% tariff on Chinese imports and additional export controls on critical U.S. software. The tariff deadline was set for November 1, while China’s overseas manufacturing rules begin December 1. That staggered timing leaves room for negotiation, but it also creates a classic market uncertainty problem: companies don’t know whether they should absorb costs, reprice products, delay production, or rework supply chains.
Markets reacted quickly. On October 10, the S&P 500 fell 2.7%, its worst day since April, while the Nasdaq dropped 3.5% and the Dow lost nearly 900 points. That’s the type of fact pattern you can use in an interview to show you understand how policy risk gets transmitted into public market volatility.
How to turn the rare earth story into an interview answer
Don’t just say, “trade tensions are bad.” That’s too generic. A stronger answer would sound more like this:
“The rare earth dispute matters because it affects the cost and availability of key inputs for semiconductors, EVs, defense equipment, and AI hardware. If Chinese approvals slow exports, manufacturers could face production delays, higher input costs, and margin pressure. Over time, that can justify higher capex for supply-chain diversification, but near term it creates uncertainty around earnings and valuation.”
That answer works because it connects macro news to company-level financials. Bankers care about that bridge. If you’re discussing a semiconductor company, you’d talk about supplier risk and inventory buffers. For an auto OEM, you’d talk about EV costs, battery and motor inputs, and manufacturing interruptions. For defense, you’d talk about supply assurance and strategic importance.
The analyst outlook also points to a broader implication: the dispute is moving beyond short-term tariffs and into competition for control of the technology supply chain. The U.S., Australia, and Canada are accelerating efforts to develop new mining and refining operations to reduce reliance on China. That creates potential long-dated investment opportunities, but these projects take time and capital.
Macro backdrop: slower growth, rate cuts, and missing data
The global macro setup is mixed. The IMF expects global growth of 2.6% by the end of 2025, down from a July forecast of 2.7% and well below 2024’s 3.6% growth. U.S. growth is projected at 1.9%, down from 2.4% in 2024 but above the prior 1.7% estimate.
That creates an awkward policy environment. Rate cuts and AI investment are supporting the economy, but monetary easing can also create inflation risk. At the same time, concerns around the labor market, state-side debt levels, and trade policy uncertainty are weighing on confidence.
Federal Reserve Chair Jerome Powell signaled the Fed remains on track to cut interest rates, citing labor market weakness. He also indicated the Fed may soon end its three-year balance sheet reduction program, which has reduced its $6.6 trillion portfolio of Treasury and mortgage-backed securities. One complication: the ongoing government shutdown has cut off access to key economic indicators used by the Fed.
For interviews, this is a useful way to talk about why valuation debates are messy right now. Lower rates can support higher multiples, especially for long-duration growth assets. But if cuts are happening because labor demand is weakening, that’s not automatically bullish. You need to discuss both sides.
Private equity in healthcare: California adds deal friction
California signed a bill expanding state authority to review healthcare transactions, with the measure taking effect in January 2026. Firms pursuing medical buyouts must submit proposed deals to the Office of Health Care Affordability, which oversees access to care and cost containment.
This follows another bill giving California more power to investigate corporate investors that interfere with patient care. Between 2019 and 2023, private equity investors spent $46.9 billion acquiring healthcare providers nationwide, including $4.3 billion in California.
The important investment banking angle is not “private equity is banned.” It isn’t. Legal experts expect the bill to make deals more time-consuming and costly, not necessarily impossible. That affects transaction timelines, diligence requirements, closing certainty, and potentially valuation. If you’re working on a healthcare deal, regulatory process can become a real execution risk.
Good interview framing: buyers may demand more protection in purchase agreements, sellers may face a narrower buyer universe, and advisors need to build longer timelines into process letters. That’s practical, banker-style thinking.
Industrial strategy is showing up in autos and chips
Automakers are adjusting to slower EV adoption and changing policy incentives. General Motors expects a $1.6 billion third-quarter charge tied to its EV strategy. Of that, $1.2 billion is non-cash from EV capacity adjustments, while $400 million is cash-related from contract cancellation fees and commercial settlements. Ford previously faced a $1.9 billion charge related to EV plan revisions.
This is a great reminder that strategy changes have accounting consequences. Capacity built for one demand curve can become impaired when adoption slows or incentives change. In valuation, you’d care about whether these are one-time charges or signs of deeper pressure on future returns on invested capital.
Stellantis is moving in the opposite direction operationally, announcing a $13 billion investment over four years to expand U.S. manufacturing. The plan includes reopening the Belvidere, Illinois plant, launching a midsize truck in Toledo, and upgrading facilities in Michigan and Indiana. The company aims to boost U.S. vehicle output by 50% and create more than 5,000 jobs.
That’s defensive and strategic at the same time. More domestic production can reduce tariff exposure and help stabilize margins, but factory retooling and supply-chain shifts carry execution risk. In an interview, that’s exactly the tradeoff you should highlight.
Intel also fits the industrial policy theme. The U.S. government announced an $8.9 billion common stock investment in Intel, equal to a passive 9.9% stake, partially funded by $5.9 billion of CHIPS Act grants and other programs. Intel’s new fabrication facilities in Arizona and Ohio are receiving early tax-credit inflows, and the company is working on its next-generation GPU, Crescent Island, slated for testing in 2026.
The recruiting angle is simple: Intel is being framed less like a normal cyclical chipmaker and more like national-security infrastructure. Whether or not you like the stock, that changes how investors may think about downside support, capex funding, and strategic relevance.
AI infrastructure is pulling in enormous capital
BlackRock, Global Infrastructure Partners, and Abu Dhabi’s MGX launched a $40 billion acquisition of Aligned Data Centers from Macquarie Asset Management. The group, called the AI Infrastructure Partnership, plans to deploy $100 billion in capital across high-efficiency data centers in the U.S. and Latin America, including $30 billion in equity and $70 billion in debt financing.
This is one of the strongest deal talking points in the entire set of developments. AI demand isn’t just about chipmakers. It’s also about power, land, data centers, leases, financing structures, and hyperscaler balance sheets. The partnership plans to lease specialized data centers to companies such as OpenAI, Google, and Meta, helping them expand computing capacity without directly carrying all the infrastructure costs.
For banking interviews, this is a great example of how infrastructure investors monetize a secular growth theme. The cash flows may look more infrastructure-like if backed by long-term leases, but the demand driver is AI growth. That combination attracts both equity and debt capital.
Private credit risk is getting harder to ignore
The collapse of First Brands Group exposed Jefferies and UBS to hidden credit risks. Jefferies’ asset management division, Point Bonita Capital, holds about $715 million in receivables tied to First Brands, while UBS-linked funds are exposed to roughly $500 million in similar financing structures.
The issue was aggressive off-balance-sheet financing that masked debt levels and reduced investor visibility. Missed payments triggered defaults across trade finance and asset-backed lending structures.
This is a useful cautionary story for candidates. Private credit and supply-chain finance can look safe because they’re tied to receivables or asset-backed structures. But complexity can hide leverage and correlated exposure. If you’re asked about credit markets, this is a concrete example of why diligence on true debt, cash conversion, and off-balance-sheet obligations matters.
M&A themes: alternatives, private data, timber, and rare disease
Several deals show where strategic buyers are still willing to pay for capabilities.
- Goldman Sachs and Industry Ventures: Goldman agreed to acquire Industry Ventures, a venture capital firm with $7 billion in assets, for $665 million upfront in cash and equity plus up to $300 million in performance-based earnouts through 2030. The deal strengthens Goldman’s $540 billion alternatives platform and adds exposure to venture secondaries.
- S&P Global and With Intelligence: S&P Global agreed to acquire With Intelligence for $1.8 billion. The target is expected to generate about $130 million of revenue in 2025 and brings private markets data, benchmarks, and workflow tools. The deal is expected to be slightly dilutive at first, with adjusted EPS gains by 2027.
- Rayonier and PotlatchDeltic: Rayonier agreed to buy PotlatchDeltic in a $3.4 billion all-stock deal, creating one of North America’s largest publicly traded timber companies with 4.2 million acres. PotlatchDeltic holders receive 1.7339 Rayonier shares per share, a 7.8% premium, while Rayonier shareholders own 54% of the combined company.
- Novo Nordisk and Omeros: Novo Nordisk agreed to acquire rights tied to Omeros’ rare-disease drug candidate Zaltenibart. Omeros is eligible for $340 million upfront and up to $2.1 billion including R&D milestones, commercial milestones, and royalties. Omeros’ stock rose from $4.05 to more than $11 after the announcement.
Each deal gives you a different technical angle. Goldman’s deal is about alternatives scale and earnout structure. S&P’s deal is about private market data and recurring analytics revenue. Rayonier-PotlatchDeltic is about stock consideration, ownership split, and vertical integration. Novo-Omeros is about milestone-heavy biotech deal structure, where the headline value is much larger than the upfront cash.
What I’d actually remember for recruiting
If you only take a few points into interviews, make them practical. Rare earth controls are a supply-chain and margin story. AI data centers are an infrastructure financing story. California healthcare regulation is a deal execution story. GM’s EV charge is a capital allocation and impairment story. First Brands is a credit diligence story.
That’s how you sound like someone thinking like a banker. Not just repeating headlines, but asking: How does this affect cash flow, risk, timing, valuation, financing, and deal certainty?